U.S. FDA Approval: MAVENCLAD® (cladribine) tablets
Category: Analytical/Test
Developers: EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada
United States
Product Description:MAVENCLAD® (cladribine) tablets are for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS) multiple sclerosis.
Developers: EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada
United States
Product Description:MAVENCLAD® (cladribine) tablets are for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS) multiple sclerosis.
Product photo